• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Cowan, Richard A
    Scarisbrick, J. J.
    Zinzani, P. L.
    Nicolay, J. P.
    Sokol, L.
    Pinter-Brown, L.
    Quaglino, P.
    Iversen, L.
    Dummer, R.
    Musiek, A.
    Foss, F.
    Ito, T.
    Rosen, J. P
    Medley, M. C.
    Show allShow less
    Affiliation
    Christie Hospital Foundation NHS Trust, University of Manchester, UK.
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background: Mogamulizumab was compared with vorinostat in the phase 3 MAVORIC trial (NCT01728805) in 372 patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had failed ≥1 prior systemic therapy. Mogamulizumab significantly prolonged progression-free survival (PFS), with a superior objective response rate (ORR) versus vorinostat. Objectives: This post hoc analysis was performed to evaluate the effect of baseline blood tumour burden on patient response to mogamulizumab. Methods: PFS, ORR, time to next treatment (TTNT), skin response (modified Severity-Weighted Assessment Tool [mSWAT]), and safety were assessed in patients stratified by blood classification (B0 [n=126], B1 [n=62], or B2 [n=184], indicating increasing blood involvement). Results: Investigator-assessed PFS was longer for mogamulizumab versus vorinostat across all blood classes; significantly so for B1 and B2 patients. ORR was higher with mogamulizumab than with vorinostat in all blood classification groups, and more markedly so with escalating B-class (B0: 15.6% vs 6.5%, P = 0.0549; B1: 25.8% vs 6.5%, P = 0.2758; B2: 37.4% vs 3.2%, P < 0.0001). TTNT was significantly longer for patients treated with mogamulizumab versus vorinostat with B1 (12.63 vs 3.07 months; HR 0.32 [95% CI 0.16-0.67]; P = 0.0018) and B2 (13.07 vs 3.53 months; HR 0.30 [95% CI 0.21-0.43]; P < 0.0001) blood involvement. In the mogamulizumab arm, 81 patients (43.5%) had ≥50% change in the mSWAT versus 41 patients (22.0%) with vorinostat; mSWAT improvements with mogamulizumab occurred most often in B1 and B2 patients. Rapid, sustained reductions were seen in CD4+ CD26- cell counts and CD4:CD8 ratios in mogamulizumab patients for all B-classes. Treatment-emergent adverse events were less frequent overall with mogamulizumab and similar in frequency regardless of B-class. Conclusions: This post hoc analysis indicates greater clinical benefit with mogamulizumab versus vorinostat in patients with MF and SS classified as having B1 and B2 blood involvement.
    Citation
    Cowan R, Scarisbrick JJ, Zinzani PL, Nicolay JP, Sokol L, Pinter‐Brown L, et al. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. Journal of the European Academy of Dermatology and Venereology. 2021 Jul 17.
    Journal
    Journal of the European Academy of Dermatology and Venereology
    URI
    http://hdl.handle.net/10541/624446
    DOI
    10.1111/jdv.17523
    PubMed ID
    34273208
    Additional Links
    https://dx.doi.org/10.1111/jdv.17523
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1111/jdv.17523
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.